Use: Labeled indications
- INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.
Full indications and usage US FDA label
INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus.
As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.
The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.
Contraindications
CONTRAINDICATIONS Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride. Hydroxyzine is contraindicated in patients with a prolonged QT interval.
Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.
Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: adults, 50 to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses.
As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg for adults and 0.6 mg/kg of body weight in children. When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally. As with all potent medication, the dosage should be adjusted according to the patient’s response to therapy.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. The extent of renal excretion of hydroxyzine has not been determined.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.
Dosage forms
Philippines
- Tablet: 10 mg, 25 mg
- Film-coated tablet: 10 mg, 25 mg
- Solution for injection: 50 mg/mL
Registered products in the Philippines
10 products registered with the Food and Drug Administration (FDA) Philippines list Hydroxyzine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products10
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
DroxiemHydroxyzine Hydrochloride | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Norris Medicines LimitedIndia | Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-11885 | Sep 27, 2028 | |
DroxiemHydroxyzine Hydrochloride | 50 mg/mL Solution For Injection (IM)Amber Glass Ampoule x 1 mL & 2 mL (Box of 10's) | Rx | Norris Medicine Ltd.India | Zyre Pharmaceuticals CorporationImporter: Medethix, Inc.Trader: Augmen Pharma, LLP | DRP-4687 | Oct 21, 2031 | |
EvazineHydroxyzine Hydrochloride | 50 mg/mL Solution for Injection (IM)Amber Glass Ampoule x 1 mL (Box of 10's); Amber Glass Ampoule x 2 mL (Box of 10's) | Rx | Norris Medicines LimitedIndia | Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-4684 | Sep 6, 2028 | |
NoneHydroxyzine (as Hydrochloride) | 10 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DR-XY41323 | Oct 18, 2031 | |
NoneHydroxyzine (as Hydrochloride) | 10 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | UNILAB, Inc.Philippines | — | DR-XY36140 | Jul 28, 2029 | |
NoneHydroxyzine Hydrochloride | 25 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | UNILAB, Inc.Philippines | — | DRP-1772 | Dec 9, 2029 | |
SedazineHydroxyzine Hydrochloride | 10 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Inc. | DRP-7082 | Dec 12, 2027 | |
Sedazine 25Hydroxyzine Hydrochloride | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Norris Medicines LimitedIndia | Vamsler Phils. Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-11885-02 | Sep 27, 2028 | |
ZiltemHydroxyzine Hydrochloride | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Norris Medicines LimitedIndia | EMCURE PHARMA PHILIPPINES INC.Importer: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-11885-01 | Sep 27, 2028 | |
Ziltem IMHydroxyzine Hydrochloride | 50 mg/mL Solution for Injection (IM)Amber Glass Ampoule x 1 mL (Box of 10's) | Rx | Norris Medicines LimitedIndia | Emcure Pharma Philippines Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-4684-01 | Sep 6, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature. Anticholinergic: Dry mouth. Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended.
Clinically significant respiratory depression has not been reported at recommended doses. Cardiac System: QT prolongation, Torsade de Pointes. In postmarketing experience, the following additional undesirable effects have been reported: Body as a Whole: Allergic reaction. Nervous System: Headache. Psychiatric: Hallucination.
Skin and Appendages: Oral hydroxyzine is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in postmarketing reports; pruritus, rash, urticaria.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally.
Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.
Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine’s clinical effects are usually noted within 15 to 30 minutes after oral administration.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Hydroxyzine (as dihydrochloride) |
| PNF listing | Oral: 25 mg tablet |
| PNF listing | Oral: 2 mg/mL syrup, 100 mL |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Hydroxyzine Hydrochloride · St Mary's Medical Park Pharmacy [US FDA-approved label, version 5, July 28, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef6a4b7-362d-61b4-e053-2995a90a0ebb
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .